In this issue of Blood, Issa et al1 report that patients with chronic-phase chronic myeloid leukemia (CML) in remission after treatment with tyrosine kinase inhibitors (TKIs) with clonal chromosomal aberrations (CCAs) in Philadelphia chromosome–negative (Ph−) metaphases had a significantly worse survival than similar patients without CCAs. This study is notable for the large number of patients with CCAs (n = 58) and the length of follow up (median, 7.6 years) (see figure).

中文翻译：

---

CCA/Ph-in CML 的预后相关性已解决

在本期血液中，Issa 等人 1 报道，在费城染色体阴性 (Ph−) 中期出现克隆性染色体畸变 (CCA) 的酪氨酸激酶抑制剂 (TKI) 治疗后，慢性期慢性粒细胞白血病 (CML) 患者获得缓解与没有 CCA 的类似患者相比，生存率明显更差。这项研究值得注意的是大量 CCA 患者（n = 58）和随访时间（中位数，7.6 年）（见图）。